During the 2013 H7N9 influenza outbreak in southeast China, there were 139 serologically confirmed cases and 48 deaths[@b1][@b2]. The H7N9 viruses were generated by the subsequent reassortment of H7 viruses with enzootic H9N2 viruses[@b3][@b4]. H7N9 infection was likely mediated by exposure to poultries because about 55.9% of H7N9 influenza patients had a clearly defined poultry exposure[@b5]. In addition, closing the poultry trading markets in China was coincided with control of the outbreak. Although many people may have contacted with these poultries, only a minority became sick[@b6][@b7], suggesting that there may be genetic determinants of both host susceptibility and severity of infection[@b8]. The acute onset and rapid progress to severe pneumonia and acute respiratory distress syndrome of H7N9 infection with high mortality highlight the importance of identifying genetic polymorphisms that might predict host response to H7N9 infection. Knowledge of these polymorphisms might help predict both susceptibility to infection and the severity of host response during potential influenza outbreaks in future.

Material and Methods
====================

Experimental Design
-------------------

This study has been approved by Ethics Committee of Fudan University and all experiments were performed in accordance with relevant guidelines and regulations of Ethics Committee of Fudan University. Due to budget limitation, we collected blood samples from 18 H7N9 infected patients during pandemic outbreak period and patients follow up after hospital discharge. We performed exon sequencing on 8 patients of the 12 survivors after H7N9 and verified all the gene mutation in all the 18 blood samples including the non-survivors ([Table 1](#t1){ref-type="table"}). Control used in house data from BGI-Shenzhen[@b9].

Sample Collection
-----------------

After informed consents were obtained from all subjects, blood samples were collected from 18 H7N9 infected patients, while exon sequencing was performed on 8 patients. Patients were considered to have H7N9 pneumonia if the following criteria were fulfilled: (1) nasopharyngeal swab positive for H7N9 and; (2) Chest X-ray or CT showing pulmonary infiltrates; (3) clinical symptom of fever and cough. This study was approved by ethical committee of Shanghai Public Health Clinical Center.

Blood collection and DNA extraction
-----------------------------------

After consent, 10 ml venous blood was drawn from each patient in an EDTA-containing tube. Samples were immediately centrifuged at 500 g for 10 min and plasma was removed and stored for future measurement. Genomic DNA was extracted from the remaining cell pellet using the SQ Blood DNA Kit II (omegabiotek D0714-250). Briefly, cells were lysed and then cell nuclei and mitochondria were separated by centrifugation. The isolated nuclei were resuspended in XL Buffer (supplied by omegabiotek) which contains chaotropic salt and proteinase to remove contamination. Lastly, genomic DNA was purified by isopropanol precipitation.

Exome capture, library preparation and sequencing
-------------------------------------------------

The isolated genomic DNA from 8 patients was fragmented into DNA strands with lengths of 150 to 200 bp by Covaris technology, and then adapters were ligated to both ends of the resulting fragments. The adapter-ligated templates were purified by the AgencourtAMPure SPRI beads and fragments with the insert size of about 200 bp were excised. Extracted DNA was amplified by ligation-mediated polymerase chain reaction (LM-PCR), purified, and hybridized to Agilent SureSelect Human All Exon (50 M) human exome array for enrichment. Hybridized fragments were bound to strepavidin beads whereas non-hybridized fragments were washed out after 24 h. Captured LM-PCR products were subjected to Agilent 2100 Bio-analyzer to estimate the magnitude of enrichment. Each captured library was then loaded on Hiseq2000 platform, and high-throughput sequencing for each captured library was performed. Raw image files were processed by Illumina base calling Software 1.7 for base calling with default parameters and the sequences of each individual were generated as 90 bp paired-end reads ([Table 2](#t2){ref-type="table"}).

Read mapping and variation detection
------------------------------------

After removing reads containing sequencing adapters and low-quality reads, high-quality reads were aligned to the NCBI human reference genome (hg19/GRCh37) using BWA (Burrows-Wheeler Aligner, v0.5.9-r16) with default parameters. Low-quality read was defined as more than half of a read was constituted with low quality bases (less than or equal to 5) or a read in which unknown bases were more than 10%. Picard (v1.54) (<http://picard.sourceforge.net/>) was used to mark duplicates. Subsequently, BAM files (sequence alignment/map format) were compressed to SAM files (the binary files of BAM files). SNPs (Single-nucleotide polymorphism) and InDels (Small insertions/deletions) were detected by module Unified Genotyper of GATK (Genome Analysis Toolkit v1.0.6076). And then ANNOVAR was used to do annotation and classification for SNPs and InDels respectively. Our data have been identified by dbSNP database (<http://www.ncbi.nlm.nih.gov/projects/SNP/snp_summary.cgi>), 1000 human genomes database ([www.1000genomes.org/](http://www.1000genomes.org/)) and BGI's inhouse control database. We used BGI's inhouse control, most controls coming from a Whole Exome Sequencing based study of genetic risk for psoriasis which has been published[@b9], and the controls comprised 800 normal people across the whole country. These inhouse control cases were specially used for analysis of rare diseases. Considering only 33 patients had confirmed H7N9 infection in Shanghai, and large population exposed to risk factors, the H7N9 infection was a low possibility case, and could be considered as rare disease, so this control data could be used in this study. We collected 40 genes which were correlated with avian influenza from HuGE Navigator by keyword search with "influenza" and extracted 89 exonic SNVs (single nucleotide variations) ([Supplementary Dataset 1](#S1){ref-type="supplementary-material"}) located in 27 genes ([Table 3](#t3){ref-type="table"}) of the 40 genes from SNPs result.

Gene mutation verification
--------------------------

The 89 mutations were verified in all the 18 patients by Sanger sequencing. 47 fragments of each patient were amplified from their genomic DNA by PrimeSTAR® HS (Premix) (Takara R040A) to verify the 89 mutated sites. The PCR products were subjected to 1% agarose gel electrophoresis and then purified from the gel by QIAquick Gel Extraction Kit (QIAGEN No. 28706). The purified PCR products were subjected to Sanger sequencing (ABI 3730).

Bioinformatics analysis
-----------------------

A protein-protein interactions (PPI) network of the resulting genes was constructed using the Disease Association Protein-Protein Link Evaluator (DAPPLE, <http://www.broadinstitute.org/mpg/dapple/dapple.php>)[@b8] with 1000 permutations selected and 2 interacting binding degree as a cutoff. And Database for Annotation, Visualization and Integrated Discovery (DAVID, <http://david.abcc.ncifcrf.gov/>)[@b10], a bioinformatics tool that can identify the biological processes, in which a group of genes are involved, were used for functional annotation.

Results
=======

Mutational Analysis of Genes from 18 H7N9 Infected patients
-----------------------------------------------------------

We have admitted 18 H7N9 infected patients around 10 days after disease onset and a series of clinical manifestation, laboratory examinations and prognosis were carried out for the following 15 weeks. 6 of the 18 patients died and we found the increased plasma CRP (Creactive protein), PCT (Procalcitonin) and virus positive days were associated with mortality[@b11]. After exon sequencing of 8 survivors, 64 exonic SNPs, located in 21 genes, were found to be enriched in the H7N9 patients compared to controls from the NCBI human genome (hg19) ([Supplementary Dataset 1](#S1){ref-type="supplementary-material"} and [Table 4](#t4){ref-type="table"}). These mutations were found in genes encoding proteins responsible for multiple key host defense mechanisms, including cytokine production, airway epithelium barrier function and pathogen associated molecular pattern signaling pathway, suggesting biological plausibility ([Table 2](#t2){ref-type="table"}).

Bioinformatics analysis
-----------------------

The resulting genes with exonic SNPs were uploaded to the online tool DAPPLE for PPI network analysis. The results indicate that the PPI network was statistically significant. There were 5 disease proteins participating in the direct network with 3 direct interactions in total expected direct interactions =  0.347, p =  0.004 ([Fig. 1](#f1){ref-type="fig"}, [Table 5](#t5){ref-type="table"}). Moreover, there were 13 genes participating in the indirect network under the same condition ([Fig. 2](#f2){ref-type="fig"}).

We further confirmed the functions of these candidate genes using the online tool DAVID. The genes were significantly enriched for defense-related processes such as response to stimulus (p =  1.81 ×  10^−8^), immune response (p =  8.85 ×  10^−7^), immune system process (p =  1.16 ×  10^−6^), response to biotic stimulus (p =  5.48 ×  10^−6^) and modulation by symbiont of host immune response (p =  1.53 ×  10^−5^) ([Table 6](#t6){ref-type="table"}).

Gene mutation distribution between different groups
---------------------------------------------------

Whole exome sequencing was performed on 8 H7N9 patients and 89 exonic SNPs were identified. These SNPs were subjected to Sanger sequencing in all the 18 patients and 64 exonic SNVs were verified. We compared the mutation rate of the case and the inhouse control using the Fisher Exact Test and found significant statistical difference ([Supplementary Dataset 1](#S1){ref-type="supplementary-material"} and [Table 4](#t4){ref-type="table"}). There were 17 SNVs significantly different between the case and the inhouse control and we have validated 16 of them by Sanger sequencing ([Table 7](#t7){ref-type="table"}). The 16 validated SNVs were located in 12 genes, and the protein-protein interaction among them ([Fig. 3](#f3){ref-type="fig"}) was consistent with the protein-protein interaction among the 21 genes done before ([Fig. 2](#f2){ref-type="fig"}). It is more likely that both the genes identified from this study that showed statistical difference of mutation frequency and the genes with same mutation rate between patients and controls have participated in the pathogenesis of H7N9 virus infection. We also did Mann-Whitney U test between the first 8 patients and the additional 10 patients and none of P-value was significant ([Table 4](#t4){ref-type="table"}), which could prove the inhouse control data do not introduce any false signals. Moreover, We compared the mutation rate of death group and survival group and analysis the mutation rate by Mann-Whitney U test and no significant difference was found between the survival and non-survival group ([Table 4](#t4){ref-type="table"}), suggesting some of genes identified in this study may be associated with H7N9 influenza susceptibility.

Discussion
==========

The 2013 Chinese H7N9 influenza outbreak lead to an estimated 48 deaths with 33% mortality and significant morbidity in patients who survived the virus. An important observation during the recent H7N9 outbreak in China was the wide variation in host response to infections, with some patients developing only mild upper respiratory tract infections, while other patients developed severe ARDS and died. Although several determinants of the host response to infection have been identified, many important genetic factors that dampen or exacerbate the host response to H7N9 infection likely remain undiscovered. Previous studies suggested that genetic mutations in the protein machinery that comprise key host defense mechanisms could impact outcomes of influenza infection[@b12]. The differential susceptibilities to influenza A(H7N9) were affected by functional variants of LGALS1 causing the expression variations[@b13]. The H7N9 influenza outbreak in China provides an unique opportunity to study mutations in this machinery, because many poultry workers were exposed to the virus, yet comparatively few became infected. This may suggest that genetic mutations in host defense mechanisms could be responsible for the selectivity of H7N9 infection. Others have identified genes that are protective during influenza infection, including MX1, NCR1, CCR5, IFITM3 and IL10[@b14]. Mutations in these genes may lead to increased host susceptibility to infection or to a heightened, and potentially deleterious, host response to infection. We hypothesized that the exome sequencing of these patients may reveal genetic mutations that increased susceptibility to viral infection, and that in the future, these mutations could provide information regarding risk of infection, especially poultry workers or family members of infected patients.

Using a variety of computational genetic techniques, we identified 21 genes that showed a high rate of mutation in patients infected with H7N9 when compared to the general population. Among these genes, some have been identified in prior studies of H7N9 susceptibility genes[@b14]. For example, Wang *et al.* reported that IFITM3 dysfunction is associated with increased cytokine production during H7N9 infection and is correlated with mortality[@b14]. IFITM3 (chr11, 320772, A \>  G) was reported to be enriched in patients hospitalized due to H1N1/09 infection[@b15]. Polymorphisms of CPT2, a carnitine palmitoyltransferase 2 protein, were found in patients suffering from influenza-associated encephalopathy; results of overexpression of CPT2 variants *in vitro* suggested that the variants were heat-labile and failed to perform optimally during fever[@b16][@b17]. Four disease outcome-associated SNPs were identified on chromosomes 17 (RPAIN and C1QBP), chromosome 1 (FCGR2A), and chromosome 3 (unknown gene). C1QBP and GCGR2A play roles in the formation of immune complexes and complement activation, suggesting that the severe disease outcome of H1N1 infection may result from an enhanced host immune response[@b12][@b16].

Among the 21 genes we identified, we use the online tool DAPPLE to performed a PPI analysis and found 5 proteins directly participates the PPI network. Those proteins include: LEP, IFNAR1, IL10RB, HLA-DQA1, HLA-DQB1. The PPI analysis suggested significant role of these proteins in influenza infection and may provide target for interventional therapy.

The primary limitation of this study is the relative small sample size. Only 18 patients were enrolled, and confirmation of these findings in subsequent studies will be needed. We are planning to collect more samples for next step sequencing.

Conclusion
==========

Using comparative genetic analysis in 18 patients with confirmed H7N9 viral infection in China, we identified 21 genetic mutations that occurred at a higher rate in infected patients when compared to the general population. Many of the identified genes are involved in key host defense mechanisms, which gives strong biologic plausibility to the role of these genes in both host susceptibility to infection as well as host immune response related pathology. Further investigations into the function of these genes in host susceptibility may help identify individuals who are at high risk for infection. In addition, translational research into the function of the genes identified in this study may provide new potential therapeutic targets for influenza virus infection.
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###### The clinical information of the 18 patients.

  Number    Survived   Exon sequencing   Poultry exposure   Admitted date   Onset date   Virus postive date
  -------- ---------- ----------------- ------------------ --------------- ------------ --------------------
  1            N              N                 N             2013.4.7      2013.3.17         2013.4.7
  2            Y              Y                 N             2013.4.13     2013.3.13        2013.4.13
  3            Y              N                 Y             2013.4.11      2013.4.4        2013.4.10
  4            Y              N                 N             2013.4.13      2013.4.4        2013.4.13
  5            Y              Y                 N             2013.4.7      2013.3.30         2013.4.6
  6            Y              N                 N             2013.4.16     2013.4.11        2013.4.16
  7            Y              N                 N             2013.4.9       2013.4.4         2013.4.8
  8            Y              Y                 N             2013.4.10      2013.4.1         2013.4.9
  9            N              N                 Y             2013.4.6      2013.3.31         2013.4.6
  10           N              N                 N             2013.4.17     2013.4.10        2013.4.16
  11           Y              Y                 N             2013.4.13      2013.4.4        2013.4.13
  12           N              N                 Y             2013.4.18      2013.4.4        2013.4.10
  13           N              N                 N             2013.4.17     2013.4.11        2013.4.16
  14           Y              Y                 N             2012.4.9       2013.4.1         2013.4.9
  15           N              N                 N             2013.4.4       2013.4.2            NA
  16           Y              Y              unknown          2013.4.21     2013.4.13        2013.4.20
  17           Y              Y                 N             2013.4.20     2013.4.13        2013.4.19
  18           Y              Y                 Y             2013.4.6       2013.4.1         2013.4.6

###### Exon sequencing data summary.

  Exome capture statistics                        Sample                                                                     
  --------------------------------------------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- -----------
  Initial bases on target                        51543125   51543125   51543125   51543125   51543125   51543125   51543125   51543125
  Total effective reads                          75899756   79734481   86586748   77653615   88308120   59564257   81497876   101930390
  Total effective yield (Mb)                     6765.23    7106.16    7730.69    6923.94    7869.24    5310.08    7276.14     9093.9
  Average read length (bp)                        89.13      89.12      89.28      89.16      89.11      89.15      89.28       89.22
  Number of reads uniquely mapped to target      37836108   36730995   37985759   37747936   38384211   35029879   37527575   38836426
  Number of reads uniquely mapped to genome      67787246   71481223   77694661   69327742   79613569   52915432   72767207   91803083
  Mismatch rate in all effective sequence (%)      0.22       0.23       0.21       0.22       0.21       0.19       0.22       0.22
  Average sequencing depth on target (X)          61.64      60.27      62.23      61.71      62.31      57.39      61.78       63.2
  Coverage of target region (%)                    98.6       99.2       99.1       99.1       98.9       98.6       99.3       99.2
  Fraction of target covered \> = 20X (%)          79.4       79.9       81.5       89.4       80.1       77.5       81.1       80.6
  Fraction of target covered \> = 10X (%)          88.8       89.6       90.4       89.7       89.4       87.9       90.2       89.9
  Fraction of target covered \> = 4X (%)           94.9       95.9       96.2       95.8       95.5       94.6       96.2        96

P, patient. The average sequencing depth on target were all more than 57X in eight samples, Coverage of target region were over 98%.

###### 21 virus infection relevant genes identified from exon sequencing.

  No     Genes                           Full name                          Chromosome loci
  ---- ---------- -------------------------------------------------------- -----------------
  1      FCGR2A                      Fc fragment of IgG                            1
  2       CPT2                carnitine palmitoyltransferase 2                     1
  3       TLR2                      toll-like receptor 2                           4
  4       TLR3                      toll-like receptor 3                           4
  5     HLA-DRB1              MHC class II DLA DRB1 beta chain                     6
  6     HLA-DQA1              MHC class II DLA DRA1 beta chain                     6
  7     HLA-DQB1   major histocompatibility complex, class II, DQ beta 1           6
  8       NOS3                    nitric oxide synthase 3                          7
  9       LEP                              leptin                                  7
  10     ABCB1               ATP-binding cassette, sub-family B                    7
  11      TLR4                      toll-like receptor 4                           9
  12     IFNAR1        interferon (alpha, beta and omega) receptor 1              21
  13     IL10RB                   interleukin 10 receptor                         21
  14      MBL2              mannose-binding lectin (protein C) 2                  10
  15     ZNF365                   zinc finger protein 365                         10
  16     IFITM3          interferon induced transmembrane protein 3               11
  17     KLRC2     killer cell lectin-like receptor subfamily C, member 2         12
  18      CES1                       carboxylesterase 1                           16
  19     RPAIN                    RPA interacting protein                         17
  20     DNMT1             DNA (cytosine-5-)-methyltransferase 1                  19
  21      MX1                     MX dynamin-like GTPase 1                        21

###### The 64 validated exonic SNVs and their distribution between different groups.

  Gene Information    Comparison between survived and deceased   Comparison between the first 8 patients and the additional 10 pateints   Comparison between case and control                                                                        
  ------------------ ------------------------------------------ ------------------------------------------------------------------------ ------------------------------------- -------- ---- --- ----- --- --- ----- -------- -------- ------------- -------------
  CPT2                                  chr1                                                    53676401                                                   T                      G      5    2    1    4   3    1     0.06    0.2104    rs2229291    0.352872195
  CPT2                                  chr1                                                    53676448                                                   G                      A      12   4   0.4   8   8   0.7    0.5     0.669     rs1799821    0.107976012
  CPT2                                  chr1                                                    53679028                                                   G                      A      1    0   0.7   1   0   0.7            0.0008                 0.019710021
  CPT2                                  chr1                                                    53679229                                                   A                      G      2    3    1    4   1    1     0.13    0.1368    rs1799822         1
  FCGR2A                                chr1                                                   161479745                                                   A                      G      6    3   0.7   3   6   0.4    0.43    0.4777    rs1801274    0.023221855
  IFITM3                               chr11                                                     320649                                                    G                      A      0    2   0.2   0   2   0.2            0.2488   rs11553885    0.140015157
  IFITM3                               chr11                                                     320772                                                    A                      G      12   5   0.1   8   9   0.2    0.21    0.3101     rs12252     0.110209014
  RPAIN                                chr17                                                    5326145                                                    C                      G      12   5   0.4   8   9   0.4    0.43    0.6017     rs12761     0.036500478
  TLR3                                  chr4                                                   187004074                                                   C                      T      9    2   0.1   6   5   0.4    0.25    0.3324    rs3775291    0.028998842
  TLR3                                  chr4                                                   187004217                                                   C                      T      5    4    1    3   9   0.1    0.28    0.3702    rs3775290    0.192232214
  TLR2                                  chr4                                                   154624656                                                   T                      C      5    5   0.7   5   5   0.7    0.43    0.4474    rs3804099    0.622004107
  TLR2                                  chr4                                                   154625259                                                   A                      G      1    0   0.7   1   0   0.7   0.0023   0.0239   rs144038898   0.32478413
  TLR2                                  chr4                                                   154625409                                                   T                      C      4    5    1    4   5    1     0.12    0.4378    rs3804100    0.801147802
  HLA-DQA1                              chr6                                                    32605284                                                   G                      A      1    0   0.2   1   0   0.2    0.06    0.0766   rs12722039    0.350824196
  HLA-DQA1                              chr6                                                    32605309                                                   A                      G      1    0   0.2   1   0   0.2    0.06    0.0622   rs12722042    0.263992352
  HLA-DQA1                              chr6                                                    32609094                                                   C                      T      2    5   0.4   2   5   0.4    0.35    0.2225    rs1129737    0.54610042
  HLA-DQA1                              chr6                                                    32609147                                                   A                      T      0    2    1    0   2    1     0.19    0.2679   rs12722051    0.262995374
  HLA-DQA1                              chr6                                                    32609173                                                   C                      G      2    5   0.2   2   5   0.2    0.4     0.2656     rs10093     0.264047871
  HLA-DQA1                              chr6                                                    32609195                                                   G                      A      1    5    1    1   5    1     0.09    0.1675   rs36219699         1
  HLA-DQA1                              chr6                                                    32609813                                                   T                      C      5    8   0.4   5   8   0.4    0.66    0.2919    rs707951     0.174782886
  HLA-DQA1                              chr6                                                    32610436                                                   T                      C      6    8   0.4   6   8   0.4    0.61    0.2679    rs1048372    0.262995374
  HLA-DQA1                              chr6                                                    32610535                                                   A                      C      6    8   0.4   6   8   0.4    0.57    0.2703    rs1130116    0.262188523
  HLA-DQB1                              chr6                                                    32629129                                                   T                      C      1    2   0.4   1   2   0.4    0.19    0.2416    rs1130432    0.384909932
  HLA-DQB1                              chr6                                                    32629155                                                   C                      A      1    2   0.4   1   2   0.4    0.23    0.2153   rs17412886    0.545857944
  HLA-DQB1                              chr6                                                    32629847                                                   A                      G      7    9   0.7   7   9   0.7    0.8     0.3541    rs1049133    0.444388806
  HLA-DQB1                              chr6                                                    32629859                                                   A                      G      6    9   0.7   6   9   0.7    0.65    0.3421    rs1049130    0.59863218
  HLA-DQB1                              chr6                                                    32629868                                                   A                      G      2    5    1    2   5   0.1    0.18    0.134     rs1049088         1
  HLA-DQB1                              chr6                                                    32629889                                                   G                      A      5    7   0.4   5   7   0.4    0.44    0.2392    rs1049087    0.385697708
  HLA-DQB1                              chr6                                                    32629904                                                   A                      G      5    6   0.4   5   6   0.4    0.6     0.2656    rs1049086    0.264047871
  HLA-DQB1                              chr6                                                    32629936                                                   C                      T      1    2   0.4   1   2   0.4    0.21    0.2057    rs1049107    0.548651412
  HLA-DQB1                              chr6                                                    32629963                                                   C                      T      1    2   0.4   1   2   0.4    0.2     0.177     rs1049100    0.752136224
  HLA-DQB1                              chr6                                                    32634313                                                   C                      G      1    2   0.4   1   2   0.4    0.21    0.0885    rs1049059    0.646223667
  HLA-DQB1                              chr6                                                    32634369                                                   C                      A      1    2   0.4   1   2   0.4    0.21    0.0981    rs1049056    0.664995324
  HLA-DRB1                              chr6                                                    32549596                                                   T                      C      8    4   0.4   8   4   0.4            0.311    rs111823233   0.171375278
  NOS3                                  chr7                                                   150695726                                                   T                      C      8    9   0.7   8   9   0.7    0.78    0.6699    rs1549758    0.182947056
  NOS3                                  chr7                                                   150696111                                                   T                      G      8    9   0.4   8   9   0.4    0.8     0.8732    rs1799983         1
  NOS3                                  chr7                                                   150704250                                                   C                      G      4    1    1    4   1    1     0.42    0.5096    rs2566514    0.04531093
  ABCB1                                 chr7                                                    87138645                                                   A                      G      7    8   0.7   7   8   0.7    0.6     0.6507    rs1045642    0.110998732
  ABCB1                                 chr7                                                    87160618                                                   A                    T or C   7    5   0.7   7   5   0.7            0.1244    rs2032582    0.709435825
  ABCB1                                 chr7                                                    87179601                                                   A                      G      3    4   0.7   3   4   0.7    0.58    0.4617    rs1128503    0.040826503
  LEP                                   chr7                                                   127892124                                                   A                      G      1    0   0.7   1   0   0.7   0.0005   0.0024   rs148407750   0.039055387
  TLR4                                  chr9                                                   120470894                                                   C                      G      1    0   0.7   1   0   0.7              --                   0.00990099
  MBL2                                 chr10                                                    54528266                                                   G                      C      8    9    1    8   9    1     0.77    0.6388    rs930507     0.194023134
  MBL2                                 chr10                                                    54531235                                                   C                      T      3    3    1    3   3    1     0.12    0.2057    rs1800450         1
  ZNF365                               chr10                                                    64159333                                                   G                      T      7    7   0.7   7   7   0.7    0.49    0.7967    rs3758490    0.11468297
  ZNF365                               chr10                                                    64415184                                                   A                      G      8    9    1    8   9    1     0.85    0.9115    rs7076156         1
  ZNF365                               chr10                                                    64416220                                                   C                      T      0    1   0.7   0   1   0.7    0.02    0.0359   rs76895268    0.444340031
  KLRC2                                chr12                                                    10587111                                                   A                      G      2    9    1    2   9    1     0.76    0.4234    rs1141715    0.003533467
  KLRC2                                chr12                                                    10588530                                                   C                      G      6    5    1    6   5    1     0.26    0.4785   rs34195537    0.004729536
  CES1                                 chr16                                                    55844509                                                   T                      C      2    0   0.7   2   0   0.7              --                   0.00990099
  CES1                                 chr16                                                    55853545                                                   C                      A      0    4   0.7   0   4   0.7    0.04    0.0407   rs115629050   0.488479286
  CES1                                 chr16                                                    55855361                                                   G                      T      1    0   0.7   1   0   0.7    0.04    0.0311    rs2307227    0.396649049
  DNMT1                                chr19                                                    10251572                                                   G                      C      1    0   0.7   1   0   0.7   0.0037   0.0072   rs144675407   0.112914886
  DNMT1                                chr19                                                    10265312                                                   T                      C      8    9   0.4   8   9   0.4    0.99    0.7297    rs721186     0.00938611
  DNMT1                                chr19                                                    10265333                                                   A                      G      1    0   0.7   1   0   0.7              --                   0.00990099
  DNMT1                                chr19                                                    10265372                                                   C                      T      1    0   0.7   1   0   0.7   0.0005     --     rs140376680   0.00990099
  DNMT1                                chr19                                                    10267077                                                   T                      C      8    7   0.4   8   7   0.4    0.54    0.6388    rs2228611    0.194023134
  DNMT1                                chr19                                                    10291181                                                   T                      C      0    2   0.2   0   2   0.2    0.06    0.3756   rs16999593    0.437380251
  IFNAR1                               chr21                                                    34715699                                                   G                      C      4    7   0.1   4   7   0.1    0.21    0.5239    rs2257167    0.129919992
  MX1                                  chr21                                                    42812891                                                   C                      T      1    2    1    1   2    1     0.36    0.177     rs467960     0.332738289
  MX1                                  chr21                                                    42817930                                                   G                      A      1    1    1    1   1    1     0.43    0.4474    rs469390     0.001564732
  MX1                                  chr21                                                    42821113                                                   T                      C      4    2   0.4   4   2   0.4    0.35    0.3278    rs2070229    0.422944246
  MX1                                  chr21                                                    42824661                                                   A                      G      4    4   0.7   4   4   0.7    0.27    0.5215    rs1050008    0.042066821
  IL10RB                               chr21                                                    34640788                                                   A                      G      8    1   0.1   8   1   0.1    0.35    0.7392    rs2834167         1

###### The PPI network statistics.

  PARAMETER                     OBSERVED    EXPECTED       P_VALUE
  ---------------------------- ---------- ------------- -------------
  Direct Edges Count               3          0.347      0.003996004
  Seed Direct Degrees Mean        1.2        0.3024      0.014985015
  Seed Indirect Degrees Mean     17.25     3.732515889   0.000999001
  CI Degrees Mean               2.096491   2.067364797   0.265734266

###### Top 10 go term analysis results.

  Term                                                                                                            Count   percentage    P-Value                                                             Genes
  -------------------------------------------------------------------------------------------------------------- ------- ------------- ---------- -------------------------------------------------------------------------------------------------------------------------
  GO:0050896:response to stimulus                                                                                  17     80.95238095   1.81E-08   HLA-DQB1, MBL2, KLRC2, CES1, HLA-DRB1, IFITM3, TLR2, TLR3, ABCB1, TLR4, HLA-DQA1, IFNAR1, LEP, RPAIN, IL10RB, NOS3, MX1
  GO:0006955:immune response                                                                                        9     42.85714286   8.85E-07                            HLA-DQB1, MBL2, HLA-DRB1, IL10RB, IFITM3, TLR2, TLR3, TLR4, HLA-DQA1
  GO:0002376:immune system process                                                                                 10     47.61904762   1.16E-06                        HLA-DQB1, MBL2, HLA-DRB1, IL10RB, IFITM3, TLR2, TLR3, TLR4, HLA-DQA1, IFNAR1
  GO:0009607:response to biotic stimulus                                                                            7     33.33333333   5.48E-06                                         IFITM3, TLR2, TLR3, NOS3, TLR4, MX1, IFNAR1
  GO:0052553:modulation by symbiont of host immune response                                                         3     14.28571429   1.53E-05                                                      TLR2, TLR3, TLR4
  GO:0052556:positive regulation by symbiont of host immune response                                                3     14.28571429   1.53E-05                                                      TLR2, TLR3, TLR4
  GO:0052166:positive regulation by symbiont of host innate immunity                                                3     14.28571429   1.53E-05                                                      TLR2, TLR3, TLR4
  GO:0052306:modulation by organism of innate immunity in other organism during symbiotic interaction               3     14.28571429   1.53E-05                                                      TLR2, TLR3, TLR4
  GO:0052305:positive regulation by organism of innate immunity in other organism during symbiotic interaction      3     14.28571429   1.53E-05                                                      TLR2, TLR3, TLR4
  GO:0052555:positive regulation by organism of immune response of other organism during symbiotic interaction      3     14.28571429   1.53E-05                                                      TLR2, TLR3, TLR4

###### The 17 SNVs significantly different between case and control.

  Gene        Chr         Pos      Ref   Obs   caseRef   caseAlt   controlRef   controlAlt    FisherExactTestPvalue   Sanger sequencing validated
  -------- ---------- ----------- ----- ----- --------- --------- ------------ ------------- ----------------------- -----------------------------
  PPARG       chr3     12475632     G     A      15         1         1600           0             0.00990099                     No
  CPT2        chr1     53679028     G     A      15         1         1599           1             0.019710021                    Yes
  FCGR2A      chr1     161479745    A     G      13         3         836           764            0.023221855                    Yes
  RPAIN      chr17      5326145     C     G       2        14         638           962            0.036500478                    Yes
  TLR3        chr4     187004074    C     T       6        10         1069          531            0.028998842                    Yes
  NOS3        chr7     150704250    C     G      12         4         785           815            0.04531093                     Yes
  ABCB1       chr7     87179601     A     G      13         3         862           738            0.040826503                    Yes
  LEP         chr7     127892124    A     G      15         1         1597           3             0.039055387                    Yes
  TLR4        chr9     120470894    C     G      15         1         1600           0             0.00990099                     Yes
  KLRC2      chr12     10587111     A     G       3        13         923           677            0.003533467                    Yes
  chr12     10588530       C        G    14       2        835        765       0.004729536            Yes           
  CES1       chr16     55844509     T     C      15         1         1600           0             0.00990099                     Yes
  DNMT1      chr19     10265312     T     C       0        16         433          1167            0.00938611                     Yes
  chr19     10265333       A        G    15       1       1600         0        0.00990099             Yes           
  chr19     10265372       C        T    15       1       1600         0        0.00990099             Yes           
  MX1        chr21     42817930     G     A      15         1         885           715            0.001564732                    Yes
  chr21     42824661       A        G    12       4        766        834       0.042066821            Yes           

[^1]: These authors contributed equally to this work.
